Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 1 (2004), Issue 5 (December)

1. Gefitinib--a novel targeted approach to treating cancer.
   Nat Rev Cancer, 4(12): 956-65. [Abstract] [Full-text]
2. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
   J Thorac Cardiovasc Surg, 128(6): 892-9. [Abstract] [Full-text]
3. Cancer incidence among pesticide applicators exposed to chlorpyrifos in the Agricultural Health Study.
   J Natl Cancer Inst, 96(23): 1781-9. [Abstract] [Full-text]
4. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
   J Natl Cancer Inst, 96(23): 1769-80. [Abstract] [Full-text]
5. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.
   J Natl Cancer Inst, 96(23): 1743-50. [Abstract] [Full-text]
6. Lung cancer: clinical presentation and specialist referral time.
   Eur Respir J, 24(6): 898-904. [Abstract] [Full-text]
7. Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus.
   Carcinogenesis, 25(12): 2293-301. [Abstract] [Full-text]
8. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
   Carcinogenesis, 25(12): 2361-72. [Abstract] [Full-text]
9. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer.
   Carcinogenesis, 25(12): 2433-41. [Abstract] [Full-text]
10. Comparison of DNA adduct levels in nasal mucosa, lymphocytes and bronchial mucosa of cigarette smokers and interaction with metabolic gene polymorphisms.
    Carcinogenesis, 25(12): 2459-65. [Abstract] [Full-text]
11. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
    Carcinogenesis, 25(12): 2451-8. [Abstract] [Full-text]
12. Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells.
    Cancer Res, 64(23): 8723-30. [Abstract] [Full-text]
13. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer.
    Cancer Res, 64(23): 8702-7. [Abstract] [Full-text]
14. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation.
    Cancer Res, 64(23): 8613-9. [Abstract] [Full-text]
15. Gene expression in the lung of p53 mutant mice exposed to cigarette smoke.
    Cancer Res, 64(23): 8566-72. [Abstract] [Full-text]
16. Metastatic myoepithelioma of the breast.
    ANZ J Surg, 74(12): 1135-7. [Abstract] [Full-text]
17. Surgical management of lung cancer in Western Australia in 1996 and its outcomes.
    ANZ J Surg, 74(12): 1076-81. [Abstract] [Full-text]
18. Radiofrequency ablation of lung malignancies: where do we stand?
    Cardiovasc Intervent Radiol, 27(6): 581-90. [Abstract] [Full-text]
19. In vivo optical imaging of pleural space drainage to lymph nodes of prognostic significance.
    Ann Surg Oncol, 11(12): 1085-92. [Abstract] [Full-text]
20. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
    Hum Mol Genet, 13(24): 3029-43. [Abstract] [Full-text]
21. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis.
    Oncogene, 23(56): 9052-61. [Abstract] [Full-text]
22. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression.
    Oncogene, 23(56): 9102-10. [Abstract] [Full-text]
23. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma.
    J Clin Endocrinol Metab, 89(12): 6146-54. [Abstract] [Full-text]
24. Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status.
    Gynecol Oncol, 95(3): 716-8. [Abstract] [Full-text]
25. Hyperpolarized (3)He MRI of mouse lung.
    Magn Reson Med, 52(6): 1310-7. [Abstract] [Full-text]
26. Regulation of lung cancer cell growth and invasiveness by beta-TRCP.
    Mol Carcinog, 42(1): 18-28. [Abstract] [Full-text]
27. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
    Int J Cancer, 113(4): 525-32. [Abstract] [Full-text]
28. Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC).
    Int J Cancer, 113(4): 568-74. [Abstract] [Full-text]
29. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.
    Eur J Nucl Med Mol Imaging, 31(12): 1614-20. [Abstract] [Full-text]
30. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
    Clin Cancer Res, 10(23): 8114-9. [Abstract] [Full-text]
31. Carbonic anhydrase IX in early-stage non-small cell lung cancer.
    Clin Cancer Res, 10(23): 7925-33. [Abstract] [Full-text]
32. Hypermethylation of the GATA genes in lung cancer.
    Clin Cancer Res, 10(23): 7917-24. [Abstract] [Full-text]
33. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
    Clin Cancer Res, 10(23): 7860-4. [Abstract] [Full-text]
34. A clinicopathologic case report of inflammatory pseudotumors involving the conjunctiva and lung.
    Jpn J Ophthalmol, 48(6): 573-7. [Abstract] [Full-text]
35. Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 55(2): 152-8. [Abstract] [Full-text]
36. Under-investigation of older people with abnormal chest radiographs.
    Gerontology, 51(1): 1-6. [Abstract] [Full-text]
37. Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC).
    Onkologie, 27(6): 583-8. [Abstract] [Full-text]
38. Disseminated microvascular pulmonary tumor cell embolism: a rare cause of fulminant pulmonary hypertension.
    Onkologie, 27(6): 566-8. [Abstract] [Full-text]
39. Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer.
    Onkologie, 27(6): 534-8. [Abstract] [Full-text]
40. Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part II-margin reduction of internal target volume.
    Int J Radiat Oncol Biol Phys, 60(5): 1473-83. [Abstract] [Full-text]
41. Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part I--correlating internal lung motion with skin fiducial motion.
    Int J Radiat Oncol Biol Phys, 60(5): 1459-72. [Abstract] [Full-text]
42. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study.
    Clin Neurophysiol, 116(1): 28-34. [Abstract] [Full-text]
43. Measurement of tumor diameter-dependent mobility of lung tumors by dynamic MRI.
    Radiother Oncol, 73(3): 349-54. [Abstract] [Full-text]
44. Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-cell lung cancer (stage I-IIIB): a phase II study.
    Radiother Oncol, 73(3): 321-4. [Abstract] [Full-text]
45. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer.
    Radiother Oncol, 73(3): 285-7. [Abstract] [Full-text]
46. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer.
    Genes Chromosomes Cancer, 42(2): 193-9. [Abstract] [Full-text]
47. G-protein inwardly rectifying potassium channel 1 (GIRK 1) gene expression correlates with tumor progression in non-small cell lung cancer.
    BMC Cancer, 4: 79. [Abstract] [Full-text]
48. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms.
    Cancer, 101(12): 2802-8. [Abstract] [Full-text]
49. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
    Cancer Chemother Pharmacol, 55(2): 197-202. [Abstract] [Full-text]
50. Endoscopic and endobronchial ultrasound real-time fine-needle aspiration for staging of the mediastinum in lung cancer.
    Chest, 126(6): 2020-2. [Abstract] [Full-text]
51. Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer.
    Chest, 126(6): 1985-93. [Abstract] [Full-text]
52. Smoking prevalence, smoking-related lung diseases, and national tobacco control legislation.
    Chest, 126(6): 1825-31. [Abstract] [Full-text]
53. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis.
    Chest, 126(6): 1750-6. [Abstract] [Full-text]
54. Benchmarking lung cancer mortality rates in current and former smokers.
    Chest, 126(6): 1742-9. [Abstract] [Full-text]
55. The relationship between cigarette smoking and quality of life after lung cancer diagnosis.
    Chest, 126(6): 1733-41. [Abstract] [Full-text]
56. Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography.
    Acad Radiol, 11(12): 1355-60. [Abstract] [Full-text]
57. Effect of temporal subtraction images on radiologists' detection of lung cancer on CT: results of the observer performance study with use of film computed tomography images.
    Acad Radiol, 11(12): 1337-43. [Abstract] [Full-text]
58. Detection of circulating tumor cells and of tumor DNA in plasma during tumor progression in rats.
    Cancer Lett, 217(1): 115-23. [Abstract] [Full-text]
59. Establishment and characterization of a rat lung adenocarcinoma cell line with low malignant potential.
    Cancer Lett, 217(1): 97-103. [Abstract] [Full-text]
60. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer.
    Int J Cancer, 113(5): 752-60. [Abstract] [Full-text]
61. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Int J Cancer, 113(5): 849-56. [Abstract] [Full-text]
62. Complex segregation analysis reveals a multigene model for lung cancer.
    Hum Genet, 116(1): 121-7. [Abstract] [Full-text]
63. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
    Ann Oncol, 16(1): 97-101. [Abstract] [Full-text]
64. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
    Ann Oncol, 16(1): 90-6. [Abstract] [Full-text]
65. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
    Ann Oncol, 16(1): 81-9. [Abstract] [Full-text]
66. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study.
    Ann Oncol, 16(1): 75-80. [Abstract] [Full-text]
67. Large cell variant of small cell carcinoma, hypercalcemic type, of primary peritoneal origin.
    Gynecol Oncol, 96(1): 249-53. [Abstract] [Full-text]
68. Recurrent small cell lung cancer presenting as bilateral adnexal masses.
    Gynecol Oncol, 96(1): 232-4. [Abstract] [Full-text]
69. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer.
    Br J Cancer, 91(12): 1993-5. [Abstract] [Full-text]
70. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.
    Br J Cancer, 91(12): 1996-2004. [Abstract] [Full-text]
71. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis.
    Br J Cancer, 91(12): 2018-25. [Abstract] [Full-text]
72. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients.
    Support Care Cancer, 12(12): 859-63. [Abstract] [Full-text]
73. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Cancer, 102(6): 368-72. [Abstract] [Full-text]
74. Family physicians' perspectives on practice guidelines related to cancer control.
    BMC Fam Pract, 5: 25. [Abstract] [Full-text]
75. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma.
    Cancer, 102(6): 348-54. [Abstract] [Full-text]
76. Myoepithelial cell-rich neoplasms: cytologic features of benign and malignant lesions.
    Cancer, 102(6): 355-61. [Abstract] [Full-text]
77. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference.
    Gene Ther, 12(1): 95-100. [Abstract] [Full-text]
78. Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice.
    Cancer Gene Ther, 12(1): 54-60. [Abstract] [Full-text]
79. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Cancer Res, 64(24): 8919-23. [Abstract] [Full-text]
80. Mediastinal emphysema and small cell lung cancer (SCLC): a case-report.
    Lung Cancer, 47(1): 139-42. [Abstract] [Full-text]
81. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
    Lung Cancer, 47(1): 129-38. [Abstract] [Full-text]
82. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
    Lung Cancer, 47(1): 121-7. [Abstract] [Full-text]
83. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Lung Cancer, 47(1): 111-20. [Abstract] [Full-text]
84. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial.
    Lung Cancer, 47(1): 103-9. [Abstract] [Full-text]
85. Adjuvant chemotherapy for radically resected non-small cell lung cancer: a retrospective analysis of 311 consecutively treated patients.
    Lung Cancer, 47(1): 93-101. [Abstract] [Full-text]
86. Long-term survivors in stage IV non-small cell lung cancer.
    Lung Cancer, 47(1): 85-91. [Abstract] [Full-text]
87. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis.
    Lung Cancer, 47(1): 81-3. [Abstract] [Full-text]
88. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
    Lung Cancer, 47(1): 69-80. [Abstract] [Full-text]
89. Sialyl Lewis antigens: association with MUC5AC protein and correlation with post-operative recurrence of non-small cell lung cancer.
    Lung Cancer, 47(1): 59-67. [Abstract] [Full-text]
90. PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy.
    Lung Cancer, 47(1): 49-57. [Abstract] [Full-text]
91. Improving the specificity of fluorescence bronchoscopy for the analysis of neoplastic lesions of the bronchial tree by combination with optical spectroscopy: preliminary communication.
    Lung Cancer, 47(1): 41-7. [Abstract] [Full-text]
92. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
    Lung Cancer, 47(1): 31-9. [Abstract] [Full-text]
93. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.
    Lung Cancer, 47(1): 17-29. [Abstract] [Full-text]
94. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer.
    Lung Cancer, 47(1): 9-15. [Abstract] [Full-text]
95. Squamous and small cell carcinomas of the lung: similarities and differences concerning the role of tobacco smoking.
    Lung Cancer, 47(1): 1-8. [Abstract] [Full-text]
96. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
    J Clin Oncol, 22(24): 4971-8. [Abstract] [Full-text]
97. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.
    J Clin Oncol, 22(24): 4966-70. [Abstract] [Full-text]
98. Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy.
    J Gastroenterol Hepatol, 19(12): 1423-6. [Abstract] [Full-text]
99. Comparison of patterns of care in lung cancer in three area health services in New South Wales, Australia.
    Intern Med J, 34(12): 677-83. [Abstract] [Full-text]
100. Successful use of intralesional and intravenous cidofovir in association with indole-3-carbinol in an 8-year-old girl with pulmonary papillomatosis.
     J Med Virol, 75(2): 332-5. [Abstract] [Full-text]
101. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan.
     JAMA, 292(24): 2984-90. [Abstract] [Full-text]
102. Familial risk of lung carcinoma in the Icelandic population.
     JAMA, 292(24): 2977-83. [Abstract] [Full-text]
103. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
     Jpn J Clin Oncol, 34(11): 647-53. [Abstract] [Full-text]
104. Pulmonary parenchymal infiltrates in a patient with CD20-positive multiple myeloma.
     Eur J Haematol, 74(1): 61-5. [Abstract] [Full-text]
105. Clinicopathological study of bronchogenic carcinoma.
     Respirology, 9(4): 557-60. [Abstract] [Full-text]
106. Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice.
     Carcinogenesis, 26(1): 209-17. [Abstract] [Full-text]
107. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
     Carcinogenesis, 26(1): 65-72. [Abstract] [Full-text]
108. Chemoradiotherapy for lung cancer: current status and perspectives.
     Int J Clin Oncol, 9(6): 435-43. [Abstract] [Full-text]
109. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review.
     Am J Epidemiol, 161(1): 1-14. [Abstract] [Full-text]
110. Choices in the management of asymptomatic lung nodules in the elderly.
     Surg Oncol, 13(4): 239-48. [Abstract] [Full-text]
111. BAG-1 haplo-insufficiency impairs lung tumorigenesis.
     BMC Cancer, 4(1): 85. [Abstract] [Full-text]
112. Bone mineral density in lymphangioleiomyomatosis.
     Am J Respir Crit Care Med, 171(1): 61-7. [Abstract] [Full-text]
113. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells.
     J Biol Chem, 279(53): 55875-85. [Abstract] [Full-text]
114. CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin.
     Eur J Cancer, 41(1): 151-8. [Abstract] [Full-text]
115. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
     Eur J Cancer, 41(1): 81-92. [Abstract] [Full-text]
116. Down-regulation of DNA polymerases kappa, eta, iota, and zeta in human lung, stomach, and colorectal cancers.
     Cancer Lett, 217(2): 139-47. [Abstract] [Full-text]
117. Pulmonary nodules on multi-detector row CT scans: performance comparison of radiologists and computer-aided detection.
     Radiology, 234(1): 274-83. [Abstract] [Full-text]
118. Establishment and characterization of a human large cell lung cancer cell line with neuroendocrine differentiation.
     Pathol Oncol Res, 10(4): 225-30. [Abstract] [Full-text]
119. Discharge independence with minimally invasive lobectomy.
     Am J Surg, 188(6): 698-702. [Abstract] [Full-text]
120. A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma.
     Cancer, 103(1): 200-8. [Abstract] [Full-text]
121. Accumulation of hRad9 protein in the nuclei of nonsmall cell lung carcinoma cells.
     Cancer, 103(1): 126-32. [Abstract] [Full-text]
122. Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen.
     Cancer, 103(1): 157-63. [Abstract] [Full-text]
123. Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer.
     Int J Cancer, 113(6): 1022-5. [Abstract] [Full-text]
124. Release of nucleophosmin from the nucleus: Involvement in aloe-emodin-induced human lung non small carcinoma cell apoptosis.
     Int J Cancer, 113(6): 971-6. [Abstract] [Full-text]
125. Outcome following surgery for primary lung cancer with interlobar pleural invasion.
     Surg Today, 35(1): 22-7. [Abstract] [Full-text]
126. Clinical evaluation of systemic inflammatory response syndrome (SIRS) in advanced lung cancer (T3 and T4) with surgical resection.
     Eur J Cardiothorac Surg, 27(1): 14-8. [Abstract] [Full-text]
127. Incidence of primary neoplasms in explanted lungs: long-term follow-up from 214 lung transplant patients.
     Transplant Proc, 36(9): 2808-11. [Abstract] [Full-text]
128. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer.
     Ann Thorac Surg, 79(1): 375-82. [Abstract] [Full-text]
129. Primary pulmonary myxoma.
     Ann Thorac Surg, 79(1): 329-30. [Abstract] [Full-text]
130. Long-term survival after salvage surgery for colorectal lung metastases.
     Ann Thorac Surg, 79(1): 325-6. [Abstract] [Full-text]
131. Video-assisted thoracoscopic surgery for pulmonary nodules after computed tomography-guided marking with a spiral wire.
     Ann Thorac Surg, 79(1): 313-6; discussion 316-7. [Abstract] [Full-text]
132. Histopathologic prognostic factors in resected colorectal lung metastases.
     Ann Thorac Surg, 79(1): 278-82; discussion 283. [Abstract] [Full-text]
133. Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans.
     Ann Thorac Surg, 79(1): 263-8. [Abstract] [Full-text]
134. Thoracoscopic localization techniques for patients with solitary pulmonary nodule and history of malignancy.
     Ann Thorac Surg, 79(1): 258-62; discussion 262. [Abstract] [Full-text]
135. Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer?
     Ann Thorac Surg, 79(1): 254-7; discussion 254-7. [Abstract] [Full-text]
136. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
     Ann Thorac Surg, 79(1): 248-53. [Abstract] [Full-text]
137. Lung cancer and its operable brain metastasis: survival rate and staging problems.
     Ann Thorac Surg, 79(1): 241-7; discussion 241-7. [Abstract] [Full-text]
138. Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer.
     Ann Thorac Surg, 79(1): 234-40. [Abstract] [Full-text]
139. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.
     Ann Thorac Surg, 79(1): 225-33. [Abstract] [Full-text]
140. Multiple ground-glass opacity in metastasis of malignant melanoma diagnosed by lung biopsy.
     Ann Thorac Surg, 79(1): e1-2. [Abstract] [Full-text]
141. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
     Clin Cancer Res, 10(24): 8656-64. [Abstract] [Full-text]
142. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
     Clin Cancer Res, 10(24): 8648-55. [Abstract] [Full-text]
143. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
     Clin Cancer Res, 10(24): 8641-7. [Abstract] [Full-text]
144. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
     Clin Cancer Res, 10(24): 8613-9. [Abstract] [Full-text]
145. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
     Clin Cancer Res, 10(24): 8587-93. [Abstract] [Full-text]
146. Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer.
     Clin Cancer Res, 10(24): 8548-53. [Abstract] [Full-text]
147. ADAM8 as a novel serological and histochemical marker for lung cancer.
     Clin Cancer Res, 10(24): 8363-70. [Abstract] [Full-text]
148. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer.
     Clin Cancer Res, 10(24): 8214-9. [Abstract] [Full-text]
149. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
     Clin Cancer Res, 10(24): 8195-203. [Abstract] [Full-text]
150. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.
     Nat Genet, 37(1): 48-55. [Abstract] [Full-text]
151. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
     J Clin Oncol, 23(1): 190-6. [Abstract] [Full-text]
152. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.
     J Clin Oncol, 23(1): 175-83. [Abstract] [Full-text]
153. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
     J Clin Oncol, 23(1): 154-64. [Abstract] [Full-text]
154. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
     J Clin Oncol, 23(1): 142-53. [Abstract] [Full-text]
155. Practical management of patients with non-small-cell lung cancer treated with gefitinib.
     J Clin Oncol, 23(1): 165-74. [Abstract] [Full-text]
156. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
     J Gene Med, 6(12): 1343-57. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.